PRESCRIPTION DRUG PRICES; Congressional Record Vol. 166, No. 7
(House of Representatives - January 13, 2020)

Text available as:

Formatting necessary for an accurate reading of this text may be shown by tags (e.g., <DELETED> or <BOLD>) or may be missing from this TXT display. For complete and accurate display of this text, see the PDF.


[Page H184]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                        PRESCRIPTION DRUG PRICES

  (Mrs. HARTZLER asked and was given permission to address the House 
for 1 minute.)
  Mrs. HARTZLER. Madam Speaker, Americans from all walks of life suffer 
because of rising healthcare costs. It is a problem that impacts 
everyone. H.R. 19, the Lower Costs, More Cures Act starts addressing 
this.
  This bill fosters competition, lowers the cost of medication, and 
spurs innovation, allowing more generic drugs to come into the market. 
One way it does this is by preventing drug companies from unfairly 
keeping generic equivalents from people who need them.
  H.R. 19 also caps prescription drug costs for Medicare beneficiaries 
and includes a smoothing out mechanism allowing seniors to distribute 
their out-of-pocket expenses throughout the year. That is why I 
cosponsored H.R. 19, the Lower Costs, More Cures Act, to take the first 
step towards making healthcare affordable. It includes nearly 50 
reforms supported by both parties, and it provides real healthcare 
solutions.
  Madam Speaker, I urge Speaker Pelosi to bring this bill to a vote, 
and I urge my colleagues to support it.

                          ____________________